EGFR-IN-165
EGFR-IN-165 is a potent EGFR inhibitor. EGFR-IN-165 demonstrates superior potency with IC50s of 17.18 and 64.74 nM against EGFRL858R/T790M and EGFRWT; 2.17 and 6.2 μM against NCI-H1975 cells and A431 cells. EGFR-IN-165 significantly inhibits the migration and induces G1 phase cell cycle arrest and cell apoptosis. EGFR-IN-165 can be used for the study of cancers such as non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; EGFR
Related Pathways
Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
COC1=C(C=C2C(N=CN=C2NC3=CC=C(C(C)=C3)C(OC4=NN=C(O4)C5=CC=CC=C5)=O)=C1)OC
Molecular Formula
C26H21N5O5
Molecular Weight
483.48
References & Citations
[1]Tang Z, et al. Design, synthesis, and evaluation of 1,3,4-oxadiazole-based EGFR inhibitors. Bioorg Med Chem Lett. 2025 Nov 1;127:130315.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items